Hikma Pharmaceuticals PLC : A trading opportunity
Entry price | Target | Stop-loss | Potential |
---|
GBX 1,653 |
GBX 0 |
GBX 1,610 |
-100% |
---|
The return on a pertinent support give a trading opportunity.
Fundamentals confirm the healthy situation of the company as analysts revisions are gradually higher concerning earnings per share. The average target price gives a 17% potential for investors.
Graphically, buyers influence have been downsized. As the trend in the short term became bearish, the test of the mid-term support at GBp 1640 should reverse the movement. Weekly moving averages are still upward oriented, a support the mid and long term trend which is bullish.
Investors should closely monitor the security near GBp 1640, to take advantage of renewed upward acceleration in the direction of GBp 1730 and GBp 1815. A stop loss will be placed at GBp 1610.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.